Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Enrolling by invitation × Cholangiocarcinoma × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 2/3 1 Phase 1/2 1

Status

Unknown 4 Recruiting 3 Active not recruiting 3 Terminated 2 Not yet recruiting 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Lymphedema 1 Leukemia, Promyelocytic, Acute 1 Cholangiocarcinoma 1

Interventions

futibatinib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡